聚乙二醇干扰素治疗慢性丙型肝炎疗效观察

目的观察聚乙二醇干扰素（PEG—IFNα-2a）治疗慢性丙型肝炎的疗效及安全性。方法60例慢性丙型肝炎患者，按治疗方案的不同分为：治疗组30例、对照组30例，治疗组给予PEG—IFNα-2a180μg或135μg，每周一次，对照组给予α-干扰素（IFNα—1b）50μg，隔天一次，两组均联合利巴韦林（900mg／d）治疗，疗程48周，随访24周。观察两组患者生化应答及病毒学应答情况。结果治疗组病毒学应答率分别为：早期病毒学应答21例（70．0％）、治疗结束时病毒学应答23例（76．3％）、持续病毒学应答16例（53．3％），与对照组的9（30．0％）、10（33．3％）、6（20．0％）例相比较，差异均有统计学意义（均P〈0．01）；两组生化应答未见明显差异（均P〉0．05）；不良反应发生率差异无统计学意义（P〉0．05）。结论PEG-IFNα-2a对慢性丙型肝炎患者的疗效优于α—1bIFN，且具有较好的安全性和耐受性。

Effect of PEG-INF alpha-2a(PEG-INF-2a)on patients With chronic hepatitis C

Objective To investigate the efficacy of PEG-INF alpha-2a(PEG-INF-2a)on patients with chronic hepatitis C.Methods 60 patients with hepatitis C were included in this study.30 patients were treated with PEGINF-2a(180μg or 135μg/week)and RBV 900mg/d,30 patients were treated with IFNα-2a(5 MIU/qod)and RBV 900 mg/d.The time of treatment was 48 weeks,and all the patients were followed up for 24 weeks after treatment.There was no significant difference between the two groups in pretreatment HCV-RNA,HCV genotype and other clinical data.The main parameters to evaluate the efficacy were virological and biochemical responses.The side effects were intensively observed.Results Sustained vimlogical response(SVR)rate in PEG-IFNα-2a group was significantly higher than that in IFNα-2a group(56.5%and 19.5%respectively,P＜0.01).As the patients were divided according to HCV genotype 1 and high virus load.the SVR rate of PEG-IFNα-2a group Was higher than IFNα-2a group(P＜0.01).However,there was no significant difference between two groups in the patients with non-genotype 1 and low viral load(P=0.664,0.116).Similar side-effects were observed in PEG IFNα-2a group and IFNα-2a group,but the rate of weisht decline and the degree of leukocyte decrease were more significant in PEG IFNα-2a group than in IFNα-2a group(P＜0.01).Conclusion The efficacy of PEG IFNα-2a in the treatment of chromic hepatitis C is superior to that of conventional IFNα-2a,PEG-IFNα-2a had good tolerance and safety profiles.